Home » DUSA PHARMACEUTICALS CLOSES ACQUISITION OF SIRIUS LABORATORIES
DUSA PHARMACEUTICALS CLOSES ACQUISITION OF SIRIUS LABORATORIES
Dusa Pharmaceuticals, Inc., developer and marketer of Levulan photodynamic therapy (PDT) for the treatment
of dermatologic conditions, announced today that it has closed the acquisition
by merger of Sirius Laboratories Inc. of Vernon Hills, Illinois ("Sirius")
into a wholly-owned subsidiary of Dusa which will be called Sirius.
Laboratories,
Inc. CCNMatthews
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
07May
-
14May
-
30May